Payment overview · 2025
General Payments
$4,212.16
187 reported records · 29 companies
Healthcare provider profile · identity verified
Gregory S. Baker, P.A.-C.
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · BAKERSFIELD, CA · NPI 1205924222
Verified facts
What the public records show
CMS Open Payments records show Gregory S. Baker, P.A.-C. received $4,212.16 in general payments during 2025 across 187 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Trintellix, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $642.10 | 15.2% | 19 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $572.81 | 13.6% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $334.42 | 7.9% | 14 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $267.10 | 6.3% | 15 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $262.84 | 6.2% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $246.41 | 5.8% | 7 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $224.77 | 5.3% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $206.15 | 4.9% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $205.25 | 4.9% | 9 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $180.70 | 4.3% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $140.86 | 3.3% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $139.97 | 3.3% | 13 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $138.82 | 3.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $84.65 | 2.0% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $78.29 | 1.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $72.33 | 1.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $70.28 | 1.7% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $42.59 | 1.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.36 | 1.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $36.58 | 0.9% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $34.34 | 0.8% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $31.40 | 0.8% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $28.69 | 0.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.14 | 0.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $27.33 | 0.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $25.81 | 0.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.58 | 0.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.05 | 0.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.54 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,120.91 | 186 |
| Education | $91.25 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $572.81 | 17 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $550.85 | 18 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $437.03 | 26 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $224.77 | 16 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $206.15 | 8 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $192.26 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $164.94 | 4 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $149.30 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $129.70 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $112.96 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $112.96 | 8 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $109.96 | 1 | 2025 |
Source payment records
|
|||||
| Cresemba Normalized: cresemba |
Drug | Astellas Pharma US Inc | $109.01 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $107.08 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $101.69 | 3 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Lundbeck LLC | $92.91 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $84.65 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $81.47 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $81.30 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $74.25 | 5 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $70.74 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $70.28 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $63.31 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $53.72 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $46.97 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $42.59 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $40.25 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $37.61 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $36.58 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $34.34 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $31.40 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.81 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $28.69 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.14 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.90 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 91 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 67 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 87 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 66 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 125 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 97 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | 22 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 20 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
97 | 22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
125 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 538 | 83 |
| Atorvastatin Calcium | Atorvastatin Calcium | 467 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 354 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 346 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 309 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 58 |
| Lisinopril | Lisinopril | 245 | 62 |
| Metformin Hcl Er | Metformin Hcl | 208 | 47 |
| Gabapentin | Gabapentin | 195 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 51 |
| Potassium Chloride | Potassium Chloride | 190 | 59 |
| Alprazolam | Alprazolam | 180 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 179 | 37 |
| Omeprazole | Omeprazole | 172 | 39 |
| Atenolol | Atenolol | 160 | 37 |
| Celecoxib | Celecoxib | 160 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 154 | 31 |
| Ibuprofen | Ibuprofen | 150 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 43 |
| Furosemide | Furosemide | 141 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 33 |
| Ozempic | Semaglutide | 125 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 26 |
| Metformin Hcl | Metformin Hcl | 114 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 23 |
| Montelukast Sodium | Montelukast Sodium | 109 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 23 |
| Nifedipine Er | Nifedipine | 103 | 25 |
| Losartan Potassium | Losartan Potassium | 102 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 102 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 102 | 21 |
| Lorazepam | Lorazepam | 99 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 97 | 22 |
| Carvedilol | Carvedilol | 91 | 20 |
| Eliquis | Apixaban | 91 | 16 |
| Pregabalin | Pregabalin | 91 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 87 | 17 |
| Jardiance | Empagliflozin | 87 | 20 |
| Simvastatin | Simvastatin | 83 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 82 | 23 |
| Meloxicam | Meloxicam | 81 | 24 |
| Azithromycin | Azithromycin | 80 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 33 |
| Famotidine | Famotidine | 79 | 23 |
| Allopurinol | Allopurinol | 77 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 17 |
| Trazodone Hcl | Trazodone Hcl | 77 | 15 |
| Ondansetron Odt | Ondansetron | 71 | 30 |
| Clonazepam | Clonazepam | 69 | 15 |
| Farxiga | Dapagliflozin Propanediol | 67 | 22 |
| Linzess | Linaclotide | 66 | 18 |
| Tramadol Hcl | Tramadol Hcl | 62 | 20 |
| Januvia | Sitagliptin Phosphate | 60 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 56 | 20 |
| Prednisone | Prednisone | 56 | 28 |
| Myrbetriq | Mirabegron | 54 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 25 |
| Meclizine Hcl | Meclizine Hcl | 52 | 25 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 49 | suppressed |
| Diazepam | Diazepam | 49 | suppressed |
| Ezetimibe | Ezetimibe | 49 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Cephalexin | Cephalexin | 43 | 38 |
| Fluconazole | Fluconazole | 40 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 16 |
| Rybelsus | Semaglutide | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 28 |
| Tresiba Flextouch U-200 | Insulin Degludec | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 12 |
| Ketoconazole | Ketoconazole | 36 | 20 |
| Rexulti | Brexpiprazole | 35 | suppressed |
| Belsomra | Suvorexant | 34 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Glipizide | Glipizide | 33 | 11 |
| Sertraline Hcl | Sertraline Hcl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 26 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 11 |
| Carisoprodol | Carisoprodol | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | 12 |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | 12 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | 16 |
| Irbesartan | Irbesartan | 24 | suppressed |
| Lactulose | Lactulose | 24 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Movantik | Naloxegol Oxalate | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 15 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 15 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Kerendia | Finerenone | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Caplyta | Lumateperone Tosylate | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,212.16 · 187 records | Teva Pharmaceuticals USA, Inc. | ABILIFY ASIMTUFII, AIRSUPRA, AREXVY, BREZTRI, CAMZYOS, CAPLYTA, CAPVAXIVE, COBENFY, CREON, Cologuard Collection Kit, Cresemba, ELIQUIS, FARXIGA, GEMTESA, INGREZZA, JARDIANCE, JOURNAVX, Kerendia, Korlym, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, Prolastin-C Liquid, RELISTOR, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, TRULANCE, UZEDY, VERQUVO, VOQUEZNA, VRAYLAR, Veozah, WAINUA, Wegovy, XIFAXAN, YUPELRI, ZENPEP, ZEPBOUND, ZORYVE | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error